Ziglim-MV 1 Tablet SR: A Synergistic Treatment for Type 2 Diabetes

Ziglim-MV 1 Tablet SR is a once-daily tablet containing a unique combination of Glimepiride (1mg), Metformin (500mg), and Voglibose (0.2mg). This combination offers a comprehensive approach to managing type 2 diabetes by addressing multiple aspects of blood sugar control.

Glimepiride: This sulfonylurea medication stimulates insulin secretion from the pancreas, effectively lowering blood glucose levels.
Metformin: A first-line treatment for type 2 diabetes, metformin exerts its effect by decreasing glucose production in the liver and improving insulin sensitivity, ultimately reducing hyperglycemia.
Voglibose: This alpha-glucosidase inhibitor slows down the breakdown of carbohydrates after they are consumed, thus preventing rapid absorption into the bloodstream and further lowering postprandial blood sugar levels.

Ziglim-MV 1 Tablet SR is formulated for optimal absorption and convenience with extended-release technology, offering consistent and sustained blood glucose control throughout the day. This medication is recommended for individuals diagnosed with type 2 diabetes by a healthcare professional.

Note: This information is intended for educational purposes only and should not be considered as medical advice. Always consult your doctor before starting any new medication regimen.